Dingdang Health Technology Group Ltd. disclosed that it repurchased 310,500 ordinary shares on 13 April 2026 via on-market transactions at prices ranging between HK$1.00 and HK$1.02 per share. The outlay for the day totalled HK$0.32 million, based on a reported aggregate consideration of HK$315,064.35.
Key takeaways
1. No change in issued share capital yet • Issued shares (excluding treasury shares) stood unchanged at 1,319.47 million between 10 April and 13 April 2026. • All repurchased shares are currently classified as “for cancellation but not yet cancelled”; therefore, they remain in the issued share count for disclosure purposes.
2. Ongoing buy-back programme • From 25 November 2025 to 13 April 2026, the company repurchased 32.03 million shares pending cancellation, representing approximately 2.43% of the issued share base on the 28 May 2025 mandate date. • Purchase prices over this period ranged from HK$0.80 to HK$1.21 per share, reflecting execution across varying market conditions.
3. Authorised capacity and restrictions • The current repurchase mandate, approved on 28 May 2025, permits Dingdang Health to buy back up to 131.95 million shares. The company has utilised 24.27% of this limit to date. • Under Hong Kong Stock Exchange rules, the issuer is subject to a moratorium on new share issues or treasury-share sales until 13 May 2026.
4. Capital management implications • Once the 32.03 million repurchased shares are formally cancelled, the outstanding share count would decline by the same amount, tightening the free float by roughly 2.4%. • No treasury shares are held; all repurchased shares are intended for cancellation, signalling an emphasis on capital reduction rather than balance-sheet deployment.
The company confirms that all repurchase activities complied with Hong Kong listing rules and the existing shareholder mandate. No new shares were issued during the period under review.
Comments